Lesly Wood
Gerontology · Fall River, MANPI 1922678564
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 362 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 28.0% of the total. Reporting peaked in 2024 at $4,162 and has fallen 66.2% since, to $1,408 in 2025. Among gerontology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 362 payments — averaging $25.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- QOL Medical, LLC$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$879
- Ardelyx, Inc.$710
- Johnson & Johnson$502
- Takeda Pharmaceuticals U.S.A., Inc.$452
- plus $3K from 21 others
What the payments were for
- Food & beverage$8,86396%
- Education$3604%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 116 | $2,582 |
| QOL Medical, LLC | 43 | $1,059 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 43 | $879 |
| Ardelyx, Inc. | 30 | $710 |
| Johnson & Johnson | 15 | $502 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $452 |
| Phathom Pharmaceuticals, Inc. | 15 | $361 |
| Sanofi | 10 | $333 |
| Gilead | 10 | $263 |
| Medical Device Business Services, Inc. | 4 | $260 |
| Pfizer | 11 | $210 |
| Lilly USA, LLC | 7 | $189 |
| Bristol Myers Squibb | 7 | $175 |
| W. L. Gore & Associates, Inc. | 1 | $148 |
| Regeneron Healthcare Solutions, Inc. | 5 | $135 |
| Ferring Pharmaceuticals Inc. | 5 | $129 |
| Novo Nordisk | 1 | $125 |
| AstraZeneca | 1 | $120 |
| Ironwood Pharmaceuticals, Inc | 5 | $103 |
| Boston Scientific | 1 | $90 |
| Philips North America LLC | 1 | $90 |
| Nestle Healthcare Nutrition Inc. | 4 | $85 |
| Stryker | 1 | $82 |
| Aimmune Therapeutics, Inc. | 2 | $56 |
| Boehringer Ingelheim | 2 | $35 |
| Madrigal Pharmaceuticals | 1 | $32 |
| Shield Therapeutics Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Skyrizi$353
- IBSRELA$263
- Creon$225
- GORE EXCLUDER AAA Endoprosthesis$148
- SURGICEL NU-KNIT$137
- Ozempic$125
- Epclusa$125
- STELARA$125
- FARXIGA$120
How this compares
$9,222 in reported general payments places this provider in the 95th percentile of 168 gerontology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SucraidSacrosidase | 15 | $111,737 |
| CreonLipase/Protease/Amylase | 48 | $101,730 |
| XifaxanRifaximin | 19 | $72,508 |
| LinzessLinaclotide | 55 | $53,908 |
| TrulancePlecanatide | 12 | $18,901 |
| VoqueznaVonoprazan Fumarate | 28 | $17,580 |
| Sucralfate | 80 | $11,032 |
| Mesalamine | 39 | $8,968 |
| Colestipol Hcl | 115 | $7,045 |
| Omeprazole | 253 | $3,787 |
| Dicyclomine Hcl | 79 | $3,291 |
| Famotidine | 207 | $3,261 |
| Dexlansoprazole DrDexlansoprazole | 15 | $2,847 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 31 | $2,151 |
| Cholestyramine LightCholestyramine | 17 | $1,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $2,582 | $155,638103 claims |
| QOL Medical, LLCSucraid | $1,059 | $111,73715 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $879 | $91,41031 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $361 | $17,58028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 168 gerontology providers in Massachusetts.
Other gerontology in Fall River
- Michelle DoranSalem$698K
- Chieu lePocasset$13K
- Theresa NguyenBoston$9K
- Lisa MendelsonBoston$6K
- Elizabeth WaithiraQuincy$4K
- Christine CorallinoBoston$4K
- Christopher EstesBoston$3K
- Ricky PamphileBoston$2K
- Kristin SkellyBoston$2K
- Natasha BurkeBoston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.